Health Care Down, but Not by Much, as Cannabis Cos Rise -- Health Care Roundup

Dow Jones05:17

Health-care companies fell, but not by as much as the broad market, after the U.S. moved closer to federal approval of the cannabis industry.

Cannabis producers rallied after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf, Canopy Growth and Tilray Brands were among the major gainers.

Novo Nordisk said it would seek approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to 17-year-olds. Novo Nordisk already sells semaglutide, a GLP-1 drug, for treatment of adult diabetes and obesity under brand names Wegovy and Ozempic.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

April 23, 2026 17:17 ET (21:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629231866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629231866","market":"us","top_or_hot":-1,"title":"Health Care Down, but Not by Much, as Cannabis Cos Rise -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell, but not by as much as the broad market, after the U.S. moved closer to federal approval of the cannabis industry. \n</p>\n<p>\n  Cannabis producers rallied after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf, <a href=\"https://laohu8.com/S/CGC\">Canopy Growth</a> and Tilray Brands were among the major gainers. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said it would seek approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to 17-year-olds. Novo Nordisk already sells semaglutide, a GLP-1 drug, for treatment of adult diabetes and obesity under brand names Wegovy and Ozempic. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 17:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down, but Not by Much, as Cannabis Cos Rise -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down, but Not by Much, as Cannabis Cos Rise -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-24 05:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell, but not by as much as the broad market, after the U.S. moved closer to federal approval of the cannabis industry. \n</p>\n<p>\n  Cannabis producers rallied after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf, <a href=\"https://laohu8.com/S/CGC\">Canopy Growth</a> and Tilray Brands were among the major gainers. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said it would seek approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to 17-year-olds. Novo Nordisk already sells semaglutide, a GLP-1 drug, for treatment of adult diabetes and obesity under brand names Wegovy and Ozempic. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 17:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629231866","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629231866","pubTimestamp":1776979020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies fell, but not by as much as the broad market, after the U.S. moved closer to federal approval of the cannabis industry.Cannabis producers rallied after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf, Canopy Growth and Tilray Brands were among the major gainers.Novo Nordisk said it would seek approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to 17-year-olds. Novo Nordisk already sells semaglutide, a GLP-1 drug, for treatment of adult diabetes and obesity under brand names Wegovy and Ozempic.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","WEED":"Roundhill Cannabis ETF","CNBS":"Amplify Seymour Cannabis ETF","MSOX":"AdvisorShares MSOX 2X Daily ETF","XBI":"SPDR S&P Biotech ETF","BK4581":"高盛持仓","TOKE":"Cambria Cannabis ETF","MJ":"Amplify Alternative Harvest ETF","YOLO":"AdvisorShares Pure Cannabis ETF","XLV":"健康照护类股ETF-SPDR","BK4588":"碎股","MSOS":"AdvisorShares Pure US Cannabis ETF","BK4585":"ETF&股票定投概念"},"translate_title":"随着大麻成本的上升，医疗保健下降，但幅度不大——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"MJ":1.5,"WEED":1.5,"XBI":0.6,"MSOS":1.5,"YOLO":1.5,"LABU":0.6,"CNBS":1.5,"MSOX":1.5,"TOKE":1.5},"content_text":"Health-care companies fell, but not by as much as the broad market, after the U.S. moved closer to federal approval of the cannabis industry. \n\n\n  Cannabis producers rallied after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf, Canopy Growth and Tilray Brands were among the major gainers. \n\n\nNovo Nordisk said it would seek approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to 17-year-olds. Novo Nordisk already sells semaglutide, a GLP-1 drug, for treatment of adult diabetes and obesity under brand names Wegovy and Ozempic. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 17:17 ET (21:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629231866","isCrawlerRequest":true}